|  | | | | | | | | Abbott Laboratories said on Friday it would release limited quantities of some nutrition products that had been on hold after the company recalled certain powder infant formulas produced at its Michigan facility. | | | | | | Pfizer Inc's vaccines head Kathrin Jansen, who led the development of the U.S. drugmaker's COVID-19 shot, has decided to retire later this year. | | | | | | The UK Health Security Agency has identified 34 confirmed hepatitis cases in children since Monday, bringing the total number to 145 amid a series of unexplained cases among children around the world. | | | | | | Russia's total number of COVID-related deaths has exceeded 803,000 since the start of the pandemic in April 2020, Reuters calculations based on new data from the Rosstat state statistics service showed on Friday. | | | | | | Scientists and health officials by this summer should have a better sense of what type of COVID-19 booster will be needed to deal with the next phase of the pandemic and when it should be administered, top U.S. infectious disease expert Dr. Anthony Fauci said on Friday. | | | | | | Canada is reviewing a request by Moderna to approve its COVID-19 vaccine for pediatric use in children aged 6 months to 5 years, the government and the company said on Friday. | | | | | | Judges on a U.S. appeals court appeared hesitant on Friday to revive a legal shield that would protect the Sackler family that owns Purdue Pharma from lawsuits related to the prescription opioid OxyContin, a key to ending the company's bankruptcy. | | | | | | The Oklahoma legislature on Thursday approved two bills that would ban virtually all abortions, and both Republican-composed laws would take effect immediately if the governor signs them as he has promised. | | | | | | Moderna Inc said on Friday it plans to build an mRNA vaccine manufacturing facility in Quebec province as part of the COVID-19 vaccine maker's 10-year partnership with the Canadian government to better prepare for future pandemics. | | | | | | GlaxoSmithKline's (GSK) COVID-19 vaccine candidate developed with SK bioscience has been submitted for regulatory approval in South Korea after positive positive Phase III clinical data, the British drugmaker said on Friday. | | | | | | | | | | | | | | | Sponsors are not involved in the creation of these or any other Reuters news articles.
Get Reuters News App
To manage which newsletters you're subscribed to, click here.
Want to stop receiving this email? Unsubscribe here.
To contact us with feedback, reply to this email. | | | | | | | | | |
